Vanda Pharmaceuticals (VNDA) opened Q1 2026 with total revenue of US$51.7 million and a basic EPS loss of US$0.82, while the trailing twelve months show revenue of US$217.8 million and a basic EPS loss of US$4.05. Over recent quarters the company has seen revenue move in a tight band between US$50.0 million and US$57.2 million and quarterly basic EPS losses range from US$0.08 to US$2.39. The latest figures fit into a pattern of steady sales alongside widening losses at the bottom line. For investors, a key question from this report is how comfortable you are with a business that is still generating meaningful revenue but where margins remain firmly in loss territory.

See our full analysis for Vanda Pharmaceuticals.

The next consideration is how these results compare with widely held views about Vanda Pharmaceuticals, highlighting where the data supports the prevailing narrative and where it may prompt investors to reassess it.

LTM losses of US$239.5 million underline profit challenge

• Over the latest twelve months Vanda reported total revenue of US$217.8 million against a net loss of US$239.5 million, so the business is currently spending more than it brings in from sales over a full year.
• Bears focus on this widening loss profile, pointing out that losses have grown at about 86.7% per year over the last five years and that forecasts still show no return to profitability in the next three years.
  • This Q1 2026 net loss of US$48.6 million follows a Q4 2025 loss of US$141.2 million, which fits the bearish concern that higher SG&A and R&D are keeping net income deep in negative territory despite fairly steady quarterly revenue in the US$50 million to US$57.2 million range.
  • With trailing twelve month basic EPS at a loss of US$4.05, critics argue that the earnings trend lines up with the view that expenses remain heavy compared with the current revenue base.

On this view, skeptics question how long the company can absorb losses of this scale before it needs either much stronger sales or a tighter cost base, and they see the recent figures as consistent with that concern. 🐻 Vanda Pharmaceuticals Bear Case

Revenue holding near US$200 million while bulls look for future ramp

• Trailing twelve month revenue has moved from US$198.8 million in Q4 2024 to US$217.8 million by Q1 2026, and forecasts point to about 20.4% annual revenue growth compared with an 11.4% US market benchmark.
• Supporters highlight this revenue profile as a foundation for the bullish view that new launches and pipeline products could lift growth, but the current numbers also show the gap that needs to be closed to match those expectations.
  • Bullish analysts are assuming future revenue growth of 36.2% a year, which is higher than the recent 20.4% forecast, so the present revenue level of US$217.8 million suggests a lot of that upside is still theoretical rather than visible in the historical figures.
  • At the same time, the quarterly revenue band of roughly US$50 million to US$57.2 million indicates a relatively stable base that bulls argue could scale if products like Fanapt and Bysanti reach the kinds of prescriber and patient metrics they expect.

For someone weighing that optimistic angle, it helps to separate what is already in the numbers from what relies on future product uptake and approvals that are not yet reflected in reported revenue. 🐂 Vanda Pharmaceuticals Bull Case

Low P/S of 1.8x versus biotech peers and volatile share price

• On valuation, Vanda is trading on a P/S of 1.8x compared with 10.9x for the US biotechs industry and 2.6x for peers, while the current share price of US$6.39 also sits well below a DCF fair value estimate of US$37.15.
• Consensus commentary often points to this wide valuation gap as a potential reward, but it also sits alongside high share price volatility and ongoing losses, which keeps the picture mixed rather than straightforward.
  • The combination of a 1.8x P/S and a DCF fair value of US$37.15 versus a US$6.39 share price lines up with the idea that the stock screens as inexpensive on simple metrics, yet the same analysis flags that the company is still unprofitable and forecast to remain so for at least three years.
  • Recent high volatility over the past three months and significant insider selling in the same period give bears more data points to question whether the apparent discount reflects genuine mispricing or simply the market reacting to the current loss profile.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Vanda Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the numbers and sentiment are clear, so do not wait for others to decide the story for you. Review the data and then weigh up the 3 key rewards and 3 important warning signs.

Explore Alternatives

Vanda Pharmaceuticals is generating meaningful revenue but continues to post sizeable losses and faces questions about how long it can sustain this loss-making profile.

If you want ideas where the focus is more on financial resilience than on turning around heavy losses, check out 72 resilient stocks with low risk scores to see stocks with steadier risk profiles that might suit a more cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.